Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HTR2C | P28335 | 3/20 | 0.33 |
| ▸ | HTR2B | P41595 | 3/20 | 0.33 |
| ▸ | ADRB2 | P07550 | 2/20 | 0.33 |
| ▸ | HTR1A | P08908 | 2/20 | 0.33 |
| ▸ | CHRM5 | P08912 | 2/20 | 0.33 |
| ▸ | ADRA2A | P08913 | 2/20 | 0.33 |
| ▸ | DRD2 | P14416 | 2/20 | 0.33 |
| ▸ | ADRA2B | P18089 | 2/20 | 0.33 |
| ▸ | ADRA2C | P18825 | 2/20 | 0.33 |
| ▸ | DRD4 | P21917 | 2/20 | 0.33 |
| ▸ | HRH2 | P25021 | 2/20 | 0.33 |
| ▸ | HTR2A | P28223 | 2/20 | 0.33 |
| ▸ | SLC6A4 | P31645 | 2/20 | 0.33 |
| ▸ | HTR7 | P34969 | 2/20 | 0.33 |
| ▸ | DRD3 | P35462 | 2/20 | 0.33 |
| ▸ | HTR6 | P50406 | 2/20 | 0.33 |
| ▸ | KCNH2 | Q12809 | 2/20 | 0.33 |
| ▸ | CA12 | O43570 | 2/20 | 0.32 |
| ▸ | CA1 | P00915 | 2/20 | 0.32 |
| ▸ | CA9 | Q16790 | 2/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5058693 | 0.93 | FTO (0.33) | PTGS1PTGS2FTO | |
| SCHEMBL27362901 | 0.80 | FTO (0.33) | FTO | |
| SCHEMBL12919726 | 0.79 | FTO (0.42) | KDM4EFTO | |
| SCHEMBL7031065 | 0.78 | ALDH1A1 (0.39) | HTR2CHTR2BCA12CA1CA9 | |
| SCHEMBL12434166 | 0.78 | ESR1 (0.36) | ALDH1A1HPGD | |
| SCHEMBL11538626 | 0.78 | — | — | |
| SCHEMBL3650395 | 0.78 | PTGDR2 (0.40) | ALDH1A1KDM4EHPGD | |
| SCHEMBL21347871 | 0.78 | FTO (0.34) | HTR2CHTR2BFTO | |
| SCHEMBL15867100 | 0.76 | ESR1 (0.34) | ALDH1A1HPGD | |
| SCHEMBL3624354 | 0.75 | FTO (0.34) | FTO |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2155178-A1 | SPIRO COMPOUNDS FOR TREATMENT OF INFLAMMATORY DISORDERS | Salutria Pharmaceuticals, LLC (US) | 2010-02-24 | — | — | EP | disclosed |
| WO-2008140781-A1 | SPIRO COMPOUNDS FOR TREATMENT OF INFLAMMATORY DISORDERS | ATHEROGENICS, INC. (US) | 2008-11-20 | — | — | WO | disclosed |
| WO-2008140781-A1 | SPIRO COMPOUNDS FOR TREATMENT OF INFLAMMATORY DISORDERS | ATHEROGENICS, INC. (US) | 2008-11-20 | — | — | WO | disclosed |
| US-20080280974-A1 | Spiro compounds for treatment of inflammatory disorders | CRABTREE ACQUISITION CO, LLC | 2008-11-13 | — | — | US | disclosed |
| US-20080280974-A1 | Spiro compounds for treatment of inflammatory disorders | CRABTREE ACQUISITION CO, LLC | 2008-11-13 | — | — | US | disclosed |
| US-20080280974-A1 | Spiro compounds for treatment of inflammatory disorders | CRABTREE ACQUISITION CO, LLC | 2008-11-13 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080280974-A1 | Spiro compounds for treatment of inflammatory disorders | NR3C2, PTGER2, PTGER1 | HTR2C 1718/4885HTR2B 1731/4885ADRB2 47/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.